drugset / Trial / NCT05003245
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
RandomizedParallel-groupDouble-blindTreatment
Summary
this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2024-05-07
- Completion
- 2024-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |